欢迎您！东篱公司
退出
-
申报数据库
-
立项数据库
-
成果数据库
-
项目获奖数据库
中文摘要：
目的构建细粒棘球绦虫重组BCG-Eg95疫苗，分析啦95分子在该疫苗中的表达效率。方法超声粉碎细粒棘球蚴组织提取总RNA，通过RT-PCR扩增印5的抗原编码基因；将该基因定向克隆到大肠杆菌．分枝杆菌穿梭表达载体pB-CG，构建重组质粒pBCG-Eg95；电穿孔法转化BCG，构建细粒棘球绦虫重组BCG-Eg95疫苗。免疫印迹分析重组BCG-Eg95疫苗的表达产物。结果RT-PCR成功扩增出471bp的Eg95抗原编码基因；双酶切证实噬95抗原编码基因成功插入pBCG中；PCR证实rBCG-Eg95疫苗构建成功；免疫印迹分析发现重组BCG-Eg95疫苗的表达产物在相对分子质量（Mt）约为16．5×10^3处有明显的目的蛋白表达条带，且能被感染细粒棘球蚴的鼠血清特异识别。结论成功构建了细粒棘球绦虫重组BCG-Eg95疫苗，为而后的开发利用奠定了理论基础。
英文摘要：
Objective To construct recombinant BCG-Eg95 vaccine of Echinococcus and analyze the expression efficiency of the gene encoding Eg95 antigen in rBCG. Methods The total RNA was extracted from hydatid cyst by ultrasound-breaking. Eg95 antigen gene amplified by RT-PCR from the total RNA was cloned into E. coli-Mycobacterium shuttle plasmid pBCG to construct pBCG-Eg95. The recombinant plasmid was electroporated into BCG to construct rBCG-Eg95 vaccine and the expression product of this vaccine was identified by Western blotting. Results Eg95 gene of 471 bp was successfully amplified by RT-PCR and cloned into pBCG by restriction analysis; rBCG- Eg95 vaccine was constructed successfully. The expression product with an approximate Mr of 16.5 ×10^3 could be recognized by sera from mice infected with CE. Conclusion rBCG-Eg95 vaccine of Echinococcus echinococcus is successfully constructed, which lays the theoretical foundation for exploitation and utilization of this vaccine.
同期刊论文项目
同项目期刊论文
期刊信息
位置：